dr. jonasch on single-agent pembrolizumab in non-clear cell rcc
Published 5 years ago • 167 plays • Length 1:14Download video MP4
Download video MP3
Similar videos
-
1:10
dr. mcdermott on the promise of pembrolizumab in non-clear cell rcc
-
0:54
dr. jonasch on promise of immuno-oncology agents in rcc
-
1:10
dr. jonasch on molecular understanding of clear cell rcc
-
1:28
keynote-b61: first-line lenvatinib pembrolizumab in non-clear cell rcc
-
0:59
combining lenvatinib & pembrolizumab for non-clear cell rcc: keynote-b61 study rationale
-
1:04
dr. jonasch on first- and second-line options for patients with rcc
-
0:57
dr. jonasch on sequencing challenges in rcc
-
1:04
dr. jonasch on modulating the tumor microenvironment in rcc
-
0:53
dr. jonasch on the potential of immunotherapy for sarcomatoid rcc
-
0:51
dr. sznol discusses immunotherapy in non-clear cell renal cancer
-
1:51
dr. srinivasan on targeted therapies for non-clear cell rcc
-
0:51
eric jonasch, md, on approaches to consider with metastatic non-clear renal cell carcinoma
-
3:04
pembrolizumab for non-clear cell rcc
-
0:25
eric jonasch, md, on targeted therapies used to treat non-clear cell renal cell carcinoma
-
5:00
keynote-b61: putting a focus on non-clear cell rcc treatment
-
1:56
dr. cost on pembrolizumab plus axitinib in patients with rcc
-
1:14
dr. jonasch on the cabosun trial in rcc
-
2:25
dr. tykodi on the keynote-427 trial with pembrolizumab in rcc
-
6:53
treatment of metastatic non-clear cell renal cell carcinoma